796 related articles for article (PubMed ID: 29967214)
1. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.
Makhov P; Joshi S; Ghatalia P; Kutikov A; Uzzo RG; Kolenko VM
Mol Cancer Ther; 2018 Jul; 17(7):1355-1364. PubMed ID: 29967214
[TBL] [Abstract][Full Text] [Related]
2. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
[TBL] [Abstract][Full Text] [Related]
3. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
4. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
[TBL] [Abstract][Full Text] [Related]
5. New agents and new targets for renal cell carcinoma.
Philips GK; Atkins MB
Am Soc Clin Oncol Educ Book; 2014; ():e222-7. PubMed ID: 24857106
[TBL] [Abstract][Full Text] [Related]
6. Strategies to overcome therapeutic resistance in renal cell carcinoma.
Siska PJ; Beckermann KE; Rathmell WK; Haake SM
Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma.
Hwang HS; Park YY; Shin SJ; Go H; Park JM; Yoon SY; Lee JL; Cho YM
J Korean Med Sci; 2020 Feb; 35(5):e31. PubMed ID: 32030920
[TBL] [Abstract][Full Text] [Related]
8. Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.
Goebell PJ; Ivanyi P; Bedke J; Bergmann L; Berthold D; Boegemann M; Busch J; Doehn C; Krege S; Retz M; Amsberg GV; Grimm MO; Gruenwald V
Future Oncol; 2020 Oct; 16(29):2307-2328. PubMed ID: 32964728
[TBL] [Abstract][Full Text] [Related]
9. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
10. Current updates and future perspectives on the management of renal cell carcinoma.
Singh D
Life Sci; 2021 Jan; 264():118632. PubMed ID: 33115605
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
12. Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies.
Xiao Y; Meierhofer D
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357507
[TBL] [Abstract][Full Text] [Related]
13. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
[TBL] [Abstract][Full Text] [Related]
14. Contemporary management of advanced renal cell carcinoma.
Khanna A; Crane A; Yerram N; Sun D; Ericson K; Lundy SD; Abouassaly R
Clin Adv Hematol Oncol; 2018 Jun; 16(6):438-446. PubMed ID: 30067615
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma.
Vuong L; Kotecha RR; Voss MH; Hakimi AA
Cancer Discov; 2019 Oct; 9(10):1349-1357. PubMed ID: 31527133
[TBL] [Abstract][Full Text] [Related]
17. Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.
Zibelman M; Plimack ER
J Natl Compr Canc Netw; 2017 Jun; 15(6):841-847. PubMed ID: 28596263
[TBL] [Abstract][Full Text] [Related]
18. Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma.
Liu W; Chen H; Wong N; Haynes W; Baker CM; Wang X
Cancer Lett; 2017 May; 394():65-75. PubMed ID: 28257806
[TBL] [Abstract][Full Text] [Related]
19. [Not Available].
Vano YA; Simonaggio A; Thibault C; Oudard S
Bull Cancer; 2018 Dec; 105 Suppl 1():S24-S34. PubMed ID: 30595195
[TBL] [Abstract][Full Text] [Related]
20. Oncotargets in different renal cancer subtypes.
Moch H; Montironi R; Lopez-Beltran A; Cheng L; Mischo A
Curr Drug Targets; 2015; 16(2):125-35. PubMed ID: 25619751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
